Peptide therapy TikTok claims: separating hype from human data
Quick answer
The creator appears to be using GHK-Cu (a copper tripeptide with documented follicle-stimulating activity in preclinical research) alongside NAD+ precursors following hair loss attributed to COVID-related telogen effluvium and caloric restriction. Telogen effluvium is self-limiting in most cases, which makes attributing observed regrowth to any specific intervention methodologically unreliable without a control condition. The gray hair reversal claim carries no meaningful clinical support from human trials as of current published literature.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @yesitsmeveronica actually say?
The creator says she lost significant hair during COVID and after weight loss, started something she calls "GHQ" (almost certainly GHK-Cu, a copper peptide), and is now seeing visible regrowth all over her scalp. She also says she's noticing fewer gray hairs, which she attributes to both NAD+ and GHK-Cu. Her words: "I am seeing less gray hairs, which is kind of crazy." She frames this as confirmation that the combination works, based entirely on her own visual observation.
To be clear about the substance: GHK-Cu is a naturally occurring copper-binding peptide. It's not a fringe compound. It appears in human plasma and has been studied for wound healing and skin biology. NAD+ precursors are a separate category entirely and she appears to be conflating two distinct mechanisms. The confidence here outpaces the evidence significantly.
Does the science back this up?
Partially, and with a lot of caveats. GHK-Cu does have real preclinical data supporting hair follicle activity, but the human trial evidence is thin and the gray hair reversal claim has almost no solid clinical backing.
A 2019 paper by Pickart and Margolina in Cosmetics summarized GHK-Cu's effects on hair follicles, noting it can stimulate follicle size and hair shaft diameter in tissue models. Separate work by Rushton (2002, Clinical and Experimental Dermatology) identified nutritional deficiencies, including those related to copper metabolism, as contributors to hair loss. So the biological plausibility exists for follicle-related effects.
On gray hair reversal: melanocyte function is complex. NAD+ precursors like NMN and NR have been studied for cellular energy metabolism, but no peer-reviewed clinical trial has demonstrated that NAD+ supplementation reverses graying in humans. A 2021 study by Covarrubias et al. in Nature Metabolism showed NAD+ metabolism influences cellular aging broadly, but graying specifically is not a validated endpoint. The claim here is a stretch.
What did they get wrong (or right)?
She got the hair regrowth plausibility partially right. COVID-related hair loss is typically telogen effluvium, a temporary shedding triggered by systemic stress. Telogen effluvium often resolves on its own within three to six months of the triggering event, regardless of intervention. Weight-loss-related shedding follows a similar pattern. Without a control condition, there is no way to know whether her regrowth is from GHK-Cu, natural recovery, improved nutrition, or time.
She got the gray hair claim wrong. Saying "I am seeing less gray hairs" and immediately crediting NAD+ and GHK-Cu is a post hoc attribution with no mechanism established in humans. Melanin production depends on melanocyte stem cell activity, oxidative stress, and follicle cycling. GHK-Cu has antioxidant properties in vitro, but that does not equal clinical gray reversal. This is the part of the video that crosses from anecdote into misinformation territory.
- COVID and weight-loss-related hair loss frequently resolves without treatment
- GHK-Cu has follicle-stimulating signals in preclinical models
- Gray hair reversal via peptides or NAD+ is not supported by clinical trials
- Her product names are unclear and she may be combining compounds without understanding their separate mechanisms
What should you actually know?
If you are considering GHK-Cu for hair loss, here is what the evidence actually supports: it has biological activity at follicle receptors, it has a reasonable safety profile in topical use, and there is early-stage human data suggesting possible benefit. That is meaningfully different from "it reversed my baldness."
For NAD+ and gray hair specifically: this claim should be treated with skepticism until a randomized controlled trial says otherwise. Correlation between starting a supplement regimen and noticing cosmetic changes is not causation. Hair also grows and changes in cycles that are influenced by stress reduction, diet changes, and dozens of other variables that shift when someone commits to a health routine.
Anyone seeing this video and interpreting it as clinical evidence is being done a disservice. The creator's experience may be real, but the explanation she offers is speculative. If hair regrowth matters to you medically, a dermatologist can assess whether your loss pattern is the kind that responds to follicle-targeted treatments, and which treatments have actual trial data behind them.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Peptide therapy TikTok claims: separating hype from human data, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
The human peptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging
Anchor review for copper peptide gene-expression and tissue-repair claims.
PubMed
Effects of glycyl-histidyl-lysine-Cu on wound healing
Search-backed PubMed trail for wound-healing claims where specific topical versus injectable context matters.
PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Peptide therapy TikTok claims: separating hype from human data is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The creator appears to be using GHK-Cu (a copper tripeptide with documented follicle-stimulating activity in preclinical research) alongside NAD+ precursors following hair loss attributed to COVID-related telogen effluvium and caloric restriction.
FormBlends verdict
The creator appears to be using GHK-Cu (a copper tripeptide with documented follicle-stimulating activity in preclinical research) alongside NAD+ precursors following hair loss attributed to COVID-related telogen effluvium and caloric restriction. Telogen effluvium is self-limiting in most cases, which makes attributing observed regrowth to any specific intervention methodologically unreliable without a control condition. The gray hair reversal claim carries no meaningful clinical support from human trials as of current published literature.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator appears to be using GHK-Cu (a copper tripeptide with documented follicle-stimulating activity in preclinical research) alongside NAD+ precursors following hair loss attributed to COVID-related telogen effluvium and caloric restriction. Telogen effluvium is self-limiting in most cases, which makes attributing observed regrowth to any specific intervention methodologically unreliable without a control condition. The gray hair reversal claim carries no meaningful clinical support from human trials as of current published literature.
- GHK-Cu has demonstrated follicle-stimulating effects in preclinical models, but randomized controlled human trial data for hair regrowth is limited as of 2024.
- COVID-related telogen effluvium resolves on its own in the majority of patients within 3-6 months, making any concurrent intervention difficult to credit for recovery (Mieczkowska et al., 2021, JEADV).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- GHK-Cu has demonstrated follicle-stimulating effects in preclinical models, but randomized controlled human trial data for hair regrowth is limited as of 2024.
- COVID-related telogen effluvium resolves on its own in the majority of patients within 3-6 months, making any concurrent intervention difficult to credit for recovery (Mieczkowska et al., 2021, JEADV).
- No published clinical trial supports the claim that NAD+ supplementation reverses hair graying in humans.
- GHK-Cu's antioxidant properties are documented in vitro, but in vitro effects do not reliably translate to clinical outcomes like melanin restoration.
- Weight-loss-related hair shedding, like stress-induced telogen effluvium, typically resolves after caloric and nutritional stabilization regardless of peptide use.
- The creator appears to conflate two distinct compounds with different proposed mechanisms, which should prompt caution about her interpretation of results.
- Anyone concerned about patterned hair loss should consult a dermatologist, as androgenetic alopecia has a different biology and treatment response profile than telogen effluvium.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Veronica Cardenas · TikTok creator
157.5K views on this video
Peptide therapy TikTok claims: separating hype from human data
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Veronica Cardenas, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.